[1]
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023 Jan:73(1):17-48. doi: 10.3322/caac.21763. Epub
[PubMed PMID: 36633525]
[2]
Wong VK, Lubner MG, Menias CO, Mellnick VM, Kennedy TA, Bhalla S, Pickhardt PJ. Clinical and Imaging Features of Noncutaneous Melanoma. AJR. American journal of roentgenology. 2017 May:208(5):942-959. doi: 10.2214/AJR.16.16800. Epub 2017 Mar 16
[PubMed PMID: 28301211]
[3]
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine. 2017 Jun 8:376(23):2211-2222. doi: 10.1056/NEJMoa1613210. Epub
[PubMed PMID: 28591523]
[4]
MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. The New England journal of medicine. 2003 Feb 6:348(6):567-8
[PubMed PMID: 12571271]
[5]
Turner N, Ware O, Bosenberg M. Genetics of metastasis: melanoma and other cancers. Clinical & experimental metastasis. 2018 Aug:35(5-6):379-391. doi: 10.1007/s10585-018-9893-y. Epub 2018 May 2
[PubMed PMID: 29722002]
[6]
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment cell & melanoma research. 2019 May:32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19
[PubMed PMID: 30712316]
[7]
Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 2019 May:9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20
[PubMed PMID: 30787016]
[8]
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of pathology & laboratory medicine. 2020 Apr:144(4):500-522. doi: 10.5858/arpa.2019-0561-RA. Epub 2020 Feb 14
[PubMed PMID: 32057276]
[9]
Friedman RJ, Rigel DS, Kopf AW, Lieblich L, Lew R, Harris MN, Roses DF, Gumport SL, Ragaz A, Waldo E, Levine J, Levenstein M, Koenig R, Bart RS, Trau H. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Archives of dermatology. 1983 Jun:119(6):455-62
[PubMed PMID: 6859885]
[10]
Motofei IG. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches. Current treatment options in oncology. 2019 May 6:20(6):45. doi: 10.1007/s11864-019-0643-4. Epub 2019 May 6
[PubMed PMID: 31056729]
[11]
Motofei IG. Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches. Melanoma research. 2019 Jun:29(3):231-236. doi: 10.1097/CMR.0000000000000573. Epub
[PubMed PMID: 30615013]
[12]
Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017 Jun 1:123(S11):2143-2153. doi: 10.1002/cncr.30444. Epub
[PubMed PMID: 28543699]
[13]
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Bénard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Human molecular genetics. 1998 Feb:7(2):209-16
[PubMed PMID: 9425228]
[14]
Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. Journal of medical genetics. 2013 Apr:50(4):264-70. doi: 10.1136/jmedgenet-2012-101455. Epub 2013 Feb 5
[PubMed PMID: 23384855]
[15]
Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature genetics. 1996 Jan:12(1):97-9
[PubMed PMID: 8528263]
[16]
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature genetics. 1994 Sep:8(1):23-6
[PubMed PMID: 7987388]
[17]
Prota G, d'Ischia M, Mascagna D. Melanogenesis as a targeting strategy against metastatic melanoma: a reassessment. Melanoma research. 1994 Dec:4(6):351-8
[PubMed PMID: 7703714]
[18]
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo (Athens, Greece). 2014 Nov-Dec:28(6):1005-11
[PubMed PMID: 25398793]
[19]
Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma. Progress in biophysics and molecular biology. 2011 Dec:107(3):362-6. doi: 10.1016/j.pbiomolbio.2011.09.011. Epub 2011 Sep 19
[PubMed PMID: 21958910]
[20]
Vosmík F. [Malignant melanoma of the skin. Epidemiology, risk factors, clinical diagnosis]. Casopis lekaru ceskych. 1996 Jul 26:135(13):405-8
[PubMed PMID: 8925536]
[21]
Lejeune FJ. Epidemiology and etiology of malignant melanoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1986:40(3):91-9
[PubMed PMID: 3527290]
[22]
O'Neill CH, Scoggins CR. Melanoma. Journal of surgical oncology. 2019 Oct:120(5):873-881. doi: 10.1002/jso.25604. Epub 2019 Jun 27
[PubMed PMID: 31246291]
[23]
Uhara H. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. International journal of clinical oncology. 2019 Dec:24(12):1508-1514. doi: 10.1007/s10147-018-1246-y. Epub 2018 Feb 22
[PubMed PMID: 29470725]
Level 3 (low-level) evidence
[24]
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. The New England journal of medicine. 2005 Nov 17:353(20):2135-47
[PubMed PMID: 16291983]
[25]
Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma research. 2006 Aug:16(4):267-73
[PubMed PMID: 16845322]
[26]
Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW, Polsky D. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004 Dec 8:292(22):2771-6
[PubMed PMID: 15585738]
[27]
Daniel Jensen J, Elewski BE. The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations. The Journal of clinical and aesthetic dermatology. 2015 Feb:8(2):15
[PubMed PMID: 25741397]
[28]
Holmes GA, Vassantachart JM, Limone BA, Zumwalt M, Hirokane J, Jacob SE. Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 2018 May:35(Suppl 4):S39-S45
[PubMed PMID: 30766399]
[29]
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017 Nov:67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13
[PubMed PMID: 29028110]
[30]
Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers. 2010 Dec 30:3(1):126-63. doi: 10.3390/cancers3010126. Epub 2010 Dec 30
[PubMed PMID: 24212610]
[31]
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep:26 Suppl 5():v126-32. doi: 10.1093/annonc/mdv297. Epub
[PubMed PMID: 26314774]
Level 1 (high-level) evidence
[32]
Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Frontiers in molecular biosciences. 2020:7():113. doi: 10.3389/fmolb.2020.00113. Epub 2020 Jun 30
[PubMed PMID: 32695793]
[33]
Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Apr 1:21(7):1326-31
[PubMed PMID: 12663722]
[34]
Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochemical pharmacology. 2014 Feb 1:87(3):381-9. doi: 10.1016/j.bcp.2013.11.013. Epub 2013 Nov 28
[PubMed PMID: 24291778]
[35]
Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA oncology. 2015 Jun:1(3):380-6. doi: 10.1001/jamaoncol.2015.0565. Epub
[PubMed PMID: 26181188]
Level 3 (low-level) evidence
[36]
Switzer B, Puzanov I, Skitzki JJ, Hamad L, Ernstoff MS. Managing Metastatic Melanoma in 2022: A Clinical Review. JCO oncology practice. 2022 May:18(5):335-351. doi: 10.1200/OP.21.00686. Epub 2022 Feb 8
[PubMed PMID: 35133862]
[37]
Urbanski A, Minnemann J, Mauch C, Schmidt T, Kreuzberg N, Schlaak M, Bruns CJ, Stippel DL, Wahba R. Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis. Langenbeck's archives of surgery. 2023 Jan 21:408(1):53. doi: 10.1007/s00423-023-02804-9. Epub 2023 Jan 21
[PubMed PMID: 36680624]
[38]
Gamboa AC, Lowe M, Yushak ML, Delman KA. Surgical Considerations and Systemic Therapy of Melanoma. The Surgical clinics of North America. 2020 Feb:100(1):141-159. doi: 10.1016/j.suc.2019.09.012. Epub 2019 Nov 1
[PubMed PMID: 31753109]
[39]
Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Mar 15:15(6):1931-9. doi: 10.1158/1078-0432.CCR-08-1980. Epub 2009 Feb 24
[PubMed PMID: 19240164]
[40]
Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL, MMAIT-IV Clinical Trial Group. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of surgical oncology. 2017 Dec:24(13):3991-4000. doi: 10.1245/s10434-017-6072-3. Epub 2017 Oct 10
[PubMed PMID: 29019177]
[41]
Janavicius M, Lachej N, Anglickiene G, Vincerzevskiene I, Brasiuniene B. Outcomes of Treatment for Melanoma Brain Metastases. Journal of skin cancer. 2020:2020():7520924. doi: 10.1155/2020/7520924. Epub 2020 Nov 5
[PubMed PMID: 33282420]
[42]
Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O, Kenai H, Moriki A, Suzuki S, Kida Y, Iwai Y, Hayashi M, Onishi H, Gondo M, Sato M, Akimitsu T, Kubo K, Kikuchi Y, Shibasaki T, Goto T, Takanashi M, Mori Y, Takakura K, Saeki N, Kunieda E, Aoyama H, Momoshima S, Tsuchiya K. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet. Oncology. 2014 Apr:15(4):387-95. doi: 10.1016/S1470-2045(14)70061-0. Epub 2014 Mar 10
[PubMed PMID: 24621620]
Level 2 (mid-level) evidence
[43]
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Sep 1:38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2
[PubMed PMID: 32484754]
Level 1 (high-level) evidence
[44]
Kodet O, Němejcova K, Strnadová K, Havlínová A, Dundr P, Krajsová I, Štork J, Smetana K Jr, Lacina L. The Abscopal Effect in the Era of Checkpoint Inhibitors. International journal of molecular sciences. 2021 Jul 4:22(13):. doi: 10.3390/ijms22137204. Epub 2021 Jul 4
[PubMed PMID: 34281259]
[45]
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Sep 1:33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26
[PubMed PMID: 26014293]
[46]
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27:417(6892):949-54
[PubMed PMID: 12068308]
[47]
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011 Jun 30:364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5
[PubMed PMID: 21639808]
[48]
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012 Feb 23:366(8):707-14. doi: 10.1056/NEJMoa1112302. Epub
[PubMed PMID: 22356324]
[49]
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology. 2018 May:19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21
[PubMed PMID: 29573941]
Level 1 (high-level) evidence
[50]
Long GV,Menzies AM,Nagrial AM,Haydu LE,Hamilton AL,Mann GJ,Hughes TM,Thompson JF,Scolyer RA,Kefford RF, Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Apr 1
[PubMed PMID: 21343559]
[51]
Johnson DB, Zhao F, Noel M, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Apr 15:26(8):1812-1819. doi: 10.1158/1078-0432.CCR-19-3443. Epub 2020 Jan 10
[PubMed PMID: 31924734]
[52]
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England journal of medicine. 2012 Nov 1:367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29
[PubMed PMID: 23020132]
[53]
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015 Jan 1:372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16
[PubMed PMID: 25399551]
[54]
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England journal of medicine. 2014 Nov 13:371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29
[PubMed PMID: 25265492]
Level 3 (low-level) evidence
[55]
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England journal of medicine. 2019 Aug 15:381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4
[PubMed PMID: 31166680]
[56]
Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nature medicine. 2019 Jun:25(6):929-935. doi: 10.1038/s41591-019-0474-7. Epub 2019 Jun 6
[PubMed PMID: 31171876]
[57]
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010 Aug 19:363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5
[PubMed PMID: 20525992]
[58]
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015 Jun 25:372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19
[PubMed PMID: 25891173]
[59]
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The New England journal of medicine. 2018 May 10:378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15
[PubMed PMID: 29658430]
[60]
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. 2015 Apr:16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18
[PubMed PMID: 25795410]
Level 1 (high-level) evidence
[61]
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA, CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New England journal of medicine. 2017 Nov 9:377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10
[PubMed PMID: 28891423]
[62]
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Oct 5:377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11
[PubMed PMID: 28889792]
[63]
Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015 Sep 29:6(29):27359-77. doi: 10.18632/oncotarget.4751. Epub
[PubMed PMID: 26318293]
[64]
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV, RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The New England journal of medicine. 2022 Jan 6:386(1):24-34. doi: 10.1056/NEJMoa2109970. Epub
[PubMed PMID: 34986285]
[65]
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C, GCC (French Group of Skin Cancer). STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. The Journal of investigative dermatology. 2018 Jan:138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24
[PubMed PMID: 28843487]
Level 1 (high-level) evidence
[66]
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer discovery. 2017 Apr:7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9
[PubMed PMID: 28183697]
[67]
Cao J, Yu Y, Zhou Y, Ji Q, Qian W, Jia D, Jin G, Qi Y, Li X, Li N, Li T, Fang M, Jin H. Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma. Frontiers in oncology. 2022:12():942258. doi: 10.3389/fonc.2022.942258. Epub 2022 Oct 20
[PubMed PMID: 36338718]
Level 2 (mid-level) evidence